629 related articles for article (PubMed ID: 15753533)
21. Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies.
Koss K; Satsangi J; Fanning GC; Welsh KI; Jewell DP
Genes Immun; 2000 Feb; 1(3):185-90. PubMed ID: 11196710
[TBL] [Abstract][Full Text] [Related]
22. The circulating common gamma chain (CD132) in inflammatory bowel disease.
Nielsen OH; Kirman I; Johnson K; Giedlin M; Ciardelli T
Am J Gastroenterol; 1998 Mar; 93(3):323-8. PubMed ID: 9517632
[TBL] [Abstract][Full Text] [Related]
23. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
[TBL] [Abstract][Full Text] [Related]
24. Soluble IL-6 receptors (sIL-6R) in hematological patients receiving immunotherapy with IL-2/IFN-alpha or donor lymphocytes following bone marrow transplantation.
Toren A; Novick D; Ackerstein A; Or R; Slavin S; Nagler A
Bone Marrow Transplant; 1996 Oct; 18(4):721-4. PubMed ID: 8899186
[TBL] [Abstract][Full Text] [Related]
25. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.
Sýkora J; Subrt I; Dìdek P; Siala K; Schwarz J; Machalová V; Varvarovská J; Pazdiora P; Pozler O; Stozický F
J Pediatr Gastroenterol Nutr; 2006 May; 42(5):479-87. PubMed ID: 16707968
[TBL] [Abstract][Full Text] [Related]
26. Serum levels of interleukin-18 (IL-18), interleukin-1beta (IL-1beta), its soluble receptor sIL-1RII and C-reactive protein (CRP) in patients with Lyme arthritis.
Pietruczuk A; Swierzbińska R; Pancewicz S; Pietruczuk M; Hermanowska-Szpakowicz T
Infection; 2006 Jun; 34(3):158-62. PubMed ID: 16804660
[TBL] [Abstract][Full Text] [Related]
27. Levels of portal and systemic blood cytokines after colectomy in patients with carcinoma or Crohn's disease.
Riché F; Dosquet C; Panis Y; Valleur P; Laisné MJ; Briard C; Wautier JL
J Am Coll Surg; 1995 Jun; 180(6):718-24. PubMed ID: 7773486
[TBL] [Abstract][Full Text] [Related]
28. Quantitative gene expression of cytokines in peripheral blood leukocytes stimulated in vitro: modulation by the anti-tumor nerosis factor-alpha antibody infliximab and comparison with the mucosal cytokine expression in patients with ulcerative colitis.
Moriconi F; Raddatz D; Ho NA; Yeruva S; Dudas J; Ramadori G
Transl Res; 2007 Oct; 150(4):223-32. PubMed ID: 17900510
[TBL] [Abstract][Full Text] [Related]
29. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model.
Chabaud M; Miossec P
Arthritis Rheum; 2001 Jun; 44(6):1293-303. PubMed ID: 11407688
[TBL] [Abstract][Full Text] [Related]
30. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis.
Tsukada Y; Nakamura T; Iimura M; Iizuka BE; Hayashi N
Am J Gastroenterol; 2002 Nov; 97(11):2820-8. PubMed ID: 12425554
[TBL] [Abstract][Full Text] [Related]
31. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
Pierik M; Vermeire S; Steen KV; Joossens S; Claessens G; Vlietinck R; Rutgeerts P
Aliment Pharmacol Ther; 2004 Aug; 20(3):303-10. PubMed ID: 15274667
[TBL] [Abstract][Full Text] [Related]
32. Soluble gp130 is up-regulated in the implantation window and shows altered secretion in patients with primary unexplained infertility.
Sherwin JR; Smith SK; Wilson A; Sharkey AM
J Clin Endocrinol Metab; 2002 Aug; 87(8):3953-60. PubMed ID: 12161539
[TBL] [Abstract][Full Text] [Related]
33. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
[TBL] [Abstract][Full Text] [Related]
34. A combination of interleukin-6 and its soluble receptor impairs sperm motility: implications in infertility associated with endometriosis.
Yoshida S; Harada T; Iwabe T; Taniguchi F; Mitsunari M; Yamauchi N; Deura I; Horie S; Terakawa N
Hum Reprod; 2004 Aug; 19(8):1821-5. PubMed ID: 15166129
[TBL] [Abstract][Full Text] [Related]
35. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.
Robak T; Wierzbowska A; Błasińska-Morawiec M; Korycka A; Błoński JZ
Mediators Inflamm; 1999; 8(6):277-86. PubMed ID: 10815616
[TBL] [Abstract][Full Text] [Related]
36. Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure.
Hirota H; Izumi M; Hamaguchi T; Sugiyama S; Murakami E; Kunisada K; Fujio Y; Oshima Y; Nakaoka Y; Yamauchi-Takihara K
Heart Vessels; 2004 Sep; 19(5):237-41. PubMed ID: 15372299
[TBL] [Abstract][Full Text] [Related]
37. IL-6 transsignaling: the in vivo consequences.
Jones SA; Richards PJ; Scheller J; Rose-John S
J Interferon Cytokine Res; 2005 May; 25(5):241-53. PubMed ID: 15871661
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-15 and its soluble receptor mediate the response to infliximab in patients with Crohn's disease.
Bouchaud G; Mortier E; Flamant M; Barbieux I; Plet A; Galmiche JP; Jacques Y; Bourreille A
Gastroenterology; 2010 Jun; 138(7):2378-87. PubMed ID: 20188102
[TBL] [Abstract][Full Text] [Related]
39. Release of interleukin-6 and its soluble receptors by activated peripheral blood monocytes is elevated in hypocholesterolemic hemodialysis patients.
Tsirpanlis G; Chatzipanagiotou S; Boufidou F; Kordinas V; Alevyzaki F; Zoga M; Kyritsis I; Ioannou D; Fatourou A; Nicolaou C
Am J Nephrol; 2005; 25(5):484-90. PubMed ID: 16127269
[TBL] [Abstract][Full Text] [Related]
40. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy?
Saniabadi AR; Hanai H; Suzuki Y; Ohmori T; Sawada K; Yoshimura N; Saito Y; Takeda Y; Umemura K; Kondo K; Ikeda Y; Fukunaga K; Nakashima M; Beretta A; Bjarnason I; Lofberg R
J Clin Apher; 2005 Oct; 20(3):171-84. PubMed ID: 15892107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
